Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Dr Reddy’s Laboratories ( (RDY) ) has provided an update.
Dr. Reddy’s Laboratories has notified stock exchanges that its board of directors will meet on May 12, 2026 to consider the audited standalone and consolidated financial results for the quarter and full financial year ended March 31, 2026. The announcement signals the upcoming close of the company’s 2025-26 financial reporting cycle, an event closely watched by investors across its Indian and U.S. listings.
In line with Indian securities regulations on insider trading, the company will impose a trading window closure for dealings in its securities from March 25, 2026 to May 14, 2026, both days inclusive. This blackout period is intended to prevent trading on unpublished price-sensitive information ahead of the release and board approval of the annual results, underscoring compliance and governance standards that are important for shareholders and regulators.
The most recent analyst rating on (RDY) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Dr Reddy’s Laboratories stock, see the RDY Stock Forecast page.
Spark’s Take on RDY Stock
According to Spark, TipRanks’ AI Analyst, RDY is a Outperform.
The score is driven primarily by strong fundamentals (profitability, growth, and low leverage), tempered by weaker cash-flow conversion. Earnings-call takeaways are moderately positive due to pipeline progress and strong liquidity, but near-term margins and regulatory delays add risk. Technicals are neutral-to-soft and valuation is reasonable with a low dividend yield.
To see Spark’s full report on RDY stock, click here.
More about Dr Reddy’s Laboratories
Dr. Reddy’s Laboratories is an India-based global pharmaceutical company headquartered in Hyderabad, focusing on generic medicines, active pharmaceutical ingredients and biosimilars for regulated markets including India, the U.S. and other international geographies. Its shares are listed in India on the NSE and BSE, and in the United States on the New York Stock Exchange, giving it broad access to domestic and global capital markets.
Average Trading Volume: 1,869,013
Technical Sentiment Signal: Hold
Current Market Cap: $11.56B
Find detailed analytics on RDY stock on TipRanks’ Stock Analysis page.